Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA..
BACKGROUND: Immunoglobulin A nephropathy (IgAN) frequently leads to kidney failure. The urinary proteomics-based classifier IgAN237 may predict disease progression at the time of kidney biopsy. We studied whether IgAN237 also predicts progression later in the course of IgAN.
METHODS: Urine from patients with biopsy-proven IgAN was analyzed using capillary electrophoresis-mass spectrometry at baseline (IgAN237-1, n = 103) and at follow-up (IgAN237-2, n = 89). Patients were categorized as "non-progressors" (IgAN237 ≤0.38) and "progressors" (IgAN237 >0.38). Estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio slopes were calculated.
RESULTS: Median age at biopsy was 44 years, interval between biopsy and IgAN237-1 was 65 months and interval between IgAN237-1 and IgAN237-2 was 258 days (interquartile range 71-531). IgAN237-1 and IgAN237-2 values did not differ significantly and were correlated (rho = 0.44, P < .001). Twenty-eight percent and 26% of patients were progressors based on IgAN237-1 and IgAN237-2, respectively. IgAN237 inversely correlated with chronic eGFR slopes (rho = -0.278, P = .02 for score-1; rho = -0.409, P = .002 for score-2) and with ±180 days eGFR slopes (rho = -0.31, P = .009 and rho = -0.439, P = .001, respectively). The ±180 days eGFR slopes were worse for progressors than for non-progressors (median -5.98 versus -1.22 mL/min/1.73 m2 per year for IgAN237-1, P < .001; -3.02 vs 1.08 mL/min/1.73 m2 per year for IgAN237-2, P = .0047). In multiple regression analysis baseline progressor/non-progressor according to IgAN237 was an independent predictor of eGFR180days-slope (P = .001).
CONCLUSION: The urinary IgAN237 classifier represents a risk stratification tool in IgAN also later in the course of the dynamic disease. It may guide patient management in an individualized manner.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association - 38(2023), 12 vom: 30. Nov., Seite 2826-2834 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Peters, Björn [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 04.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ndt/gfad125 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358513367 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358513367 | ||
| 003 | DE-627 | ||
| 005 | 20231226074913.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ndt/gfad125 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358513367 | ||
| 035 | |a (NLM)37349951 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Peters, Björn |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 04.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. | ||
| 520 | |a BACKGROUND: Immunoglobulin A nephropathy (IgAN) frequently leads to kidney failure. The urinary proteomics-based classifier IgAN237 may predict disease progression at the time of kidney biopsy. We studied whether IgAN237 also predicts progression later in the course of IgAN | ||
| 520 | |a METHODS: Urine from patients with biopsy-proven IgAN was analyzed using capillary electrophoresis-mass spectrometry at baseline (IgAN237-1, n = 103) and at follow-up (IgAN237-2, n = 89). Patients were categorized as "non-progressors" (IgAN237 ≤0.38) and "progressors" (IgAN237 >0.38). Estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio slopes were calculated | ||
| 520 | |a RESULTS: Median age at biopsy was 44 years, interval between biopsy and IgAN237-1 was 65 months and interval between IgAN237-1 and IgAN237-2 was 258 days (interquartile range 71-531). IgAN237-1 and IgAN237-2 values did not differ significantly and were correlated (rho = 0.44, P < .001). Twenty-eight percent and 26% of patients were progressors based on IgAN237-1 and IgAN237-2, respectively. IgAN237 inversely correlated with chronic eGFR slopes (rho = -0.278, P = .02 for score-1; rho = -0.409, P = .002 for score-2) and with ±180 days eGFR slopes (rho = -0.31, P = .009 and rho = -0.439, P = .001, respectively). The ±180 days eGFR slopes were worse for progressors than for non-progressors (median -5.98 versus -1.22 mL/min/1.73 m2 per year for IgAN237-1, P < .001; -3.02 vs 1.08 mL/min/1.73 m2 per year for IgAN237-2, P = .0047). In multiple regression analysis baseline progressor/non-progressor according to IgAN237 was an independent predictor of eGFR180days-slope (P = .001) | ||
| 520 | |a CONCLUSION: The urinary IgAN237 classifier represents a risk stratification tool in IgAN also later in the course of the dynamic disease. It may guide patient management in an individualized manner | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CKD | |
| 650 | 4 | |a IgA nephropathy | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a glomerulonephritis | |
| 650 | 4 | |a progression | |
| 650 | 4 | |a urine proteomics | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Beige, Joachim |e verfasserin |4 aut | |
| 700 | 1 | |a Siwy, Justyna |e verfasserin |4 aut | |
| 700 | 1 | |a Rudnicki, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Wendt, Ralph |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Ana Belen |e verfasserin |4 aut | |
| 700 | 1 | |a Mischak, Harald |e verfasserin |4 aut | |
| 700 | 1 | |a Reich, Heather N |e verfasserin |4 aut | |
| 700 | 1 | |a Nasic, Salmir |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmood, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Persson, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Fernström, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Weiner, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Stegmayr, Bernd |e verfasserin |4 aut | |
| 700 | 0 | |a PersTIgAN Working Group |e verfasserin |4 aut | |
| 700 | 1 | |a Beige, Joachim |e investigator |4 oth | |
| 700 | 1 | |a Wendt, Ralph |e investigator |4 oth | |
| 700 | 1 | |a Schmidt, Ulrike |e investigator |4 oth | |
| 700 | 1 | |a Siwy, Justyna |e investigator |4 oth | |
| 700 | 1 | |a Zürbig, Petra |e investigator |4 oth | |
| 700 | 1 | |a Mischak, Harald |e investigator |4 oth | |
| 700 | 1 | |a Durban, Annika |e investigator |4 oth | |
| 700 | 1 | |a Raad, Julia |e investigator |4 oth | |
| 700 | 1 | |a Golovko, Igor |e investigator |4 oth | |
| 700 | 1 | |a Reich, Heather |e investigator |4 oth | |
| 700 | 1 | |a Lam, Ping |e investigator |4 oth | |
| 700 | 1 | |a Yang, Stuart |e investigator |4 oth | |
| 700 | 1 | |a Sanz, Ana Belen |e investigator |4 oth | |
| 700 | 1 | |a Fernandez-Fernandez, Beatriz |e investigator |4 oth | |
| 700 | 1 | |a Rojas-Rivera, Jorge Enrique |e investigator |4 oth | |
| 700 | 1 | |a Perez-Gomez, Maria Vanessa |e investigator |4 oth | |
| 700 | 1 | |a Ortiz, Alberto |e investigator |4 oth | |
| 700 | 1 | |a Sanchez-Niño, Maria Dolores |e investigator |4 oth | |
| 700 | 1 | |a Sanchez-Rodriguez, Jinny |e investigator |4 oth | |
| 700 | 1 | |a Rudnicki, Michael |e investigator |4 oth | |
| 700 | 1 | |a Kerschbaum, Julia |e investigator |4 oth | |
| 700 | 1 | |a Leierer, Johannes |e investigator |4 oth | |
| 700 | 1 | |a Mayer, Gert |e investigator |4 oth | |
| 700 | 1 | |a Stegmayr, Bernd |e investigator |4 oth | |
| 700 | 1 | |a Peters, Björn |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association |d 1990 |g 38(2023), 12 vom: 30. Nov., Seite 2826-2834 |w (DE-627)NLM012639206 |x 1460-2385 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:12 |g day:30 |g month:11 |g pages:2826-2834 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ndt/gfad125 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 12 |b 30 |c 11 |h 2826-2834 | ||